Cingulate Inc
CING3.970USD
+0.110+2.85%
收盘 12/19, 16:00（美东）报价延迟15分钟
23.73M总市值
亏损市盈率 TTM
关于 Cingulate Inc 公司
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Cingulate Inc简介
公司代码CING
公司名称Cingulate Inc
上市日期Oct 07, 2021
CEOCallahan (Jennifer L)
员工数量13
证券类型Ordinary Share
年结日Oct 07
公司地址1901 W. 47Th Place
城市KANSAS CITY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编66205
电话19139422300
网址https://www.cingulate.com/
公司代码CING
上市日期Oct 07, 2021
CEOCallahan (Jennifer L)
Cingulate Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
Dr. Matthew N. (Matt) Brams, M.D.
Dr. Matthew N. (Matt) Brams, M.D.
Co-Founder, Executive Vice President, Chief Medical Officer
Co-Founder, Executive Vice President, Chief Medical Officer
--
--
Mr. Nilay Patel, J.D.
Mr. Nilay Patel, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Peter J. Werth
Mr. Peter J. Werth
Director
Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Bryan Lawrence
Mr. Bryan Lawrence
Independent Director
Independent Director
--
--
Mr. Thomas Dalton
Mr. Thomas Dalton
Vice President, Investor and Public Relations
Vice President, Investor and Public Relations
--
--
Mr. John A. (Jay) Roberts
Mr. John A. (Jay) Roberts
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Raul R. Silva, M.D.
Dr. Raul R. Silva, M.D.
Co-Founder, Executive Vice President, Chief Science Officer
Co-Founder, Executive Vice President, Chief Science Officer
--
--
Ms. Jennifer L. Callahan
Ms. Jennifer L. Callahan
Interim Chief Executive Officer, Chief Financial Officer
Interim Chief Executive Officer, Chief Financial Officer
--
--
Mr. Jeffrey S. (Jeff) Ervin
Mr. Jeffrey S. (Jeff) Ervin
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
其他
95.08%
持股股东
持股股东
占比
Werth Family Investment Associates LLC
1.45%
Kestra Advisory Services, LLC
1.39%
The Vanguard Group, Inc.
1.09%
Geode Capital Management, L.L.C.
0.63%
Quantum Private Wealth, LLC
0.36%
其他
95.08%
股东类型
持股股东
占比
Investment Advisor
3.35%
Corporation
1.50%
Investment Advisor/Hedge Fund
0.75%
Research Firm
0.27%
其他
94.13%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
33
295.34K
5.70%
--
2025Q3
44
295.34K
6.89%
+113.00
2025Q2
41
295.23K
5.36%
+158.62K
2025Q1
38
136.60K
4.92%
-48.84K
2024Q4
38
91.23K
3.95%
+40.70K
2024Q3
38
50.54K
3.01%
-30.23K
2024Q2
36
80.24K
1.97%
+46.92K
2024Q1
36
33.32K
1.85%
+25.60K
2023Q4
33
318.00
10.05%
-5.36K
2023Q3
30
5.68K
6.07%
+3.89K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Werth Family Investment Associates LLC
97.99K
1.75%
--
--
Aug 01, 2025
The Vanguard Group, Inc.
35.38K
0.63%
+24.62K
+228.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
32.16K
0.57%
+1.76K
+5.78%
Jun 30, 2025
Quantum Private Wealth, LLC
10.00K
0.18%
--
--
Jun 30, 2025
LPL Financial LLC
12.18K
0.22%
+12.18K
--
Jun 30, 2025
Virtu Americas LLC
13.35K
0.24%
+13.35K
--
Jun 30, 2025
BofA Global Research (US)
7.50K
0.13%
+5.54K
+283.09%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
公告日期
类型
比率
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Aug 07, 2024
Merger
12→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
Nov 28, 2023
Merger
20→1
常见问题
Cingulate Inc的前五大股东是谁？
Cingulate Inc 的前五大股东如下：
Werth Family Investment Associates LLC持有股份：97.99K，占总股份比例：1.75%。
The Vanguard Group, Inc.持有股份：35.38K，占总股份比例：0.63%。
Geode Capital Management, L.L.C.持有股份：32.16K，占总股份比例：0.57%。
Quantum Private Wealth, LLC持有股份：10.00K，占总股份比例：0.18%。
LPL Financial LLC持有股份：12.18K，占总股份比例：0.22%。
Werth Family Investment Associates LLC持有股份：97.99K，占总股份比例：1.75%。
The Vanguard Group, Inc.持有股份：35.38K，占总股份比例：0.63%。
Geode Capital Management, L.L.C.持有股份：32.16K，占总股份比例：0.57%。
Quantum Private Wealth, LLC持有股份：10.00K，占总股份比例：0.18%。
LPL Financial LLC持有股份：12.18K，占总股份比例：0.22%。
Cingulate Inc的前三大股东类型是什么？
Cingulate Inc 的前三大股东类型分别是：
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
Werth Family Investment Associates LLC
Kestra Advisory Services, LLC
The Vanguard Group, Inc.
有多少机构持有Cingulate Inc(CING)的股份？
截至2025Q4，共有33家机构持有Cingulate Inc的股份，合计持有的股份价值约为295.34K，占公司总股份的5.70%。与2025Q3相比，机构持股有所增加，增幅为-1.19%。
哪个业务部门对Cingulate Inc的收入贡献最大？
在--，--业务部门对Cingulate Inc的收入贡献最大，创收--，占总收入的--%。
